Drugs / VNZ/TEZ/D-IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07349394 | Jan → Feb 2026 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNZ/TEZ/D-IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07349394 ↗ |
| Route | Oral | “Fixed-dose combination (FDC) Tablet for oral administration.” NCT07349394 ↗ |